IN2014DN09594A - - Google Patents
Download PDFInfo
- Publication number
- IN2014DN09594A IN2014DN09594A IN9594DEN2014A IN2014DN09594A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A IN 9594DEN2014 A IN9594DEN2014 A IN 9594DEN2014A IN 2014DN09594 A IN2014DN09594 A IN 2014DN09594A
- Authority
- IN
- India
- Prior art keywords
- ophthalmological
- vehicle system
- eye
- cornea
- active substance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168139.9A EP2664329A1 (fr) | 2012-05-15 | 2012-05-15 | Système de véhicule ophtalmologique |
| PCT/EP2013/059927 WO2013171204A2 (fr) | 2012-05-15 | 2013-05-14 | Système ophtalmologique de véhicule de substances médicamenteuses, kit ophtalmologique, et utilisation d'une composition ophtalmologique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN09594A true IN2014DN09594A (fr) | 2015-07-31 |
Family
ID=48463974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN9594DEN2014 IN2014DN09594A (fr) | 2012-05-15 | 2013-05-14 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150139973A1 (fr) |
| EP (2) | EP2664329A1 (fr) |
| JP (1) | JP2015521182A (fr) |
| KR (1) | KR20150014966A (fr) |
| CN (1) | CN104394859A (fr) |
| AU (1) | AU2013261873A1 (fr) |
| CA (1) | CA2873265A1 (fr) |
| HK (1) | HK1202427A1 (fr) |
| IN (1) | IN2014DN09594A (fr) |
| MX (1) | MX2014013884A (fr) |
| RU (1) | RU2014145440A (fr) |
| WO (1) | WO2013171204A2 (fr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2952209T (pt) * | 2014-06-04 | 2018-05-09 | Alfasigma Spa | Formulações homogéneas compreendendo ácidos gordos poliinsaturados ómega-3 (n-3 pufa) e resveratrol para administração oral |
| WO2015188103A1 (fr) * | 2014-06-06 | 2015-12-10 | Archer Daniels Midland Company | Microémulsions et utilisations desdites microémulsions |
| AU2015329609B2 (en) * | 2014-10-09 | 2021-01-21 | Distretto Tecnologico Sicilia Micro E Nano Sistemi S.C.A.R.L. | Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases |
| CN107106325B (zh) | 2015-01-12 | 2021-05-25 | 科达莱昂治疗公司 | 微滴递送设备和方法 |
| AU2016246060B2 (en) | 2015-04-10 | 2020-10-22 | Bausch + Lomb Ireland Limited | Piezoelectric dispenser with replaceable ampoule |
| WO2016181998A1 (fr) * | 2015-05-12 | 2016-11-17 | ライオン株式会社 | Composition ophtalmologique |
| WO2017025471A1 (fr) * | 2015-08-07 | 2017-02-16 | Gene Signal International Sa | Émulsion stérile comprenant un oligonucléotide phosphorothioate stable |
| EP3128007A1 (fr) * | 2015-08-07 | 2017-02-08 | Gene Signal International SA | Émulsion stérile comprenant un oligonucléotide de phosphorothioate stable |
| US10780171B2 (en) | 2015-10-26 | 2020-09-22 | President And Fellows Of Harvard College | Reduced and oxidized polysaccharides and methods of use thereof |
| WO2018077958A1 (fr) | 2016-10-27 | 2018-05-03 | Unilever N.V. | Composition de soins personnels comprenant des curcuminoïdes |
| JP6134853B1 (ja) * | 2016-10-28 | 2017-05-24 | 参天製薬株式会社 | エピナスチン含有点眼液 |
| CA3039106A1 (fr) | 2017-01-20 | 2018-07-26 | Kedalion Therapeutics, Inc. | Distributeur de fluide piezoelectrique |
| US10052343B1 (en) | 2017-02-03 | 2018-08-21 | Gene Signal International Sa | Sterile formulation comprising a stable phosphorothioate oligonucleotide |
| JP6635974B2 (ja) * | 2017-04-24 | 2020-01-29 | 参天製薬株式会社 | エピナスチン含有点眼液 |
| CN107158020A (zh) * | 2017-05-18 | 2017-09-15 | 德施普科技发展温州有限公司 | 一种眼科用药物组合物及其制备方法 |
| AU2018380433B2 (en) | 2017-12-08 | 2024-10-10 | Bausch + Lomb Ireland Limited | Fluid delivery alignment system |
| KR102094882B1 (ko) * | 2017-12-21 | 2020-04-28 | 주식회사 유엠아이옵틱스 | 항균 누점 플러그 및 그 제조방법 |
| WO2019191800A1 (fr) * | 2018-04-04 | 2019-10-10 | Eye Co Pty Ltd | Extrait de chanvre contenant une faible quantité de thc et méthode de traitement ou de prévention d'une maladie oculaire |
| US12350194B1 (en) | 2018-04-12 | 2025-07-08 | Bausch + Lomb Ireland Limited | Topical ocular delivery of fluids with controlled mass dosing and wireless communication |
| US20190314197A1 (en) | 2018-04-12 | 2019-10-17 | Kedalion Therapeutics, Inc. | Topical Ocular Delivery Methods and Devices for Use in the Same |
| DE102018208110A1 (de) | 2018-05-23 | 2019-11-28 | F. Holzer Gmbh | Abgabekopf und Abgabevorrichtung zur dosierten Abgabe flüssiger Präparate sowie Verwendungsmöglichkeiten |
| WO2020010116A1 (fr) | 2018-07-03 | 2020-01-09 | Kedalion Therapeutics, Inc. | Dispositifs d'administration oculaire topique et leurs procédés d'utilisation |
| WO2020047197A1 (fr) * | 2018-08-29 | 2020-03-05 | Ocugen, Inc. | Compositions ophtalmiques et méthodes d'utilisation |
| WO2020070751A1 (fr) * | 2018-10-03 | 2020-04-09 | Tathagata Dutta | Forme galénique semi-solide pour administration d'antioxydants par voie ophtalmique |
| US12097145B2 (en) | 2019-03-06 | 2024-09-24 | Bausch + Lomb Ireland Limited | Vented multi-dose ocular fluid delivery system |
| US11679028B2 (en) | 2019-03-06 | 2023-06-20 | Novartis Ag | Multi-dose ocular fluid delivery system |
| WO2020227210A1 (fr) * | 2019-05-03 | 2020-11-12 | Mark Lobanoff | Éclairage proche infrarouge pour intervention chirurgicale |
| CN114245737A (zh) * | 2019-06-11 | 2022-03-25 | 司斐股份有限公司 | 微乳剂组合物 |
| CN110384584A (zh) * | 2019-06-28 | 2019-10-29 | 四川省一直牛健康管理有限公司 | 一款中西方芳香植物配伍的功能性眼罩及其制备方法 |
| WO2021049864A1 (fr) * | 2019-09-11 | 2021-03-18 | (주) 메드빌 | Composition permettant d'améliorer le syndrome de l'œil sec contenant un extrait d'aralia elata |
| US12496218B1 (en) | 2019-11-12 | 2025-12-16 | Bausch + Lomb Ireland Limited | Fractionated topical ocular drug delivery methods and devices for use in the same |
| JP6736752B2 (ja) * | 2019-12-17 | 2020-08-05 | 参天製薬株式会社 | エピナスチン含有点眼液 |
| CN111269161B (zh) * | 2019-12-26 | 2022-03-08 | 深圳市真兴生物医药研究中心有限公司 | 厚朴酚与萝卜硫素拼接物及其制备方法和应用 |
| EP4118212A4 (fr) * | 2020-03-13 | 2024-05-22 | Furst-McNess Company | Compositions et procédés fournissant des avantages nutritionnels et autres et ayant des propriétés antivirales |
| WO2021212038A1 (fr) | 2020-04-17 | 2021-10-21 | Kedalion Therapeutics, Inc. | Système de distribution sans conservateur à actionnement hydrodynamique comprenant un réservoir de liquide pliable |
| US12290472B2 (en) | 2020-04-17 | 2025-05-06 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| IL297215A (en) | 2020-04-17 | 2022-12-01 | Kedallon Therapeutics Inc | A hydrodynamically activated preservative free distribution system |
| US11938057B2 (en) | 2020-04-17 | 2024-03-26 | Bausch + Lomb Ireland Limited | Hydrodynamically actuated preservative free dispensing system |
| EP3919047A1 (fr) * | 2020-06-03 | 2021-12-08 | AZAD Pharma AG | Microémulsion pour le traitement du syndrome de l' il sec |
| WO2021257636A1 (fr) * | 2020-06-15 | 2021-12-23 | University Of Utah Research Foundation | Biodisponibilité rétinienne d'acides gras polyinsaturés à très longue chaîne synthétiques |
| JP2020169213A (ja) * | 2020-07-15 | 2020-10-15 | 参天製薬株式会社 | エピナスチン含有点眼液 |
| WO2022018605A1 (fr) * | 2020-07-19 | 2022-01-27 | Narayana Nethralaya Foundation | Formulation de combinaison de génistéine et de calcitriol pour la gestion d'états inflammatoires de surface oculaire |
| US11033516B1 (en) | 2020-09-18 | 2021-06-15 | Spring Discovery, Inc. | Combination therapies with disulfiram |
| WO2022065436A1 (fr) * | 2020-09-25 | 2022-03-31 | 株式会社イーダーム | Agent prophylactique, agent d'amélioration et agent thérapeutique pour la sécheresse oculaire |
| IT202000026236A1 (it) * | 2020-11-04 | 2022-05-04 | Iromed Group S R L | Composizione oftalmica |
| WO2023146984A1 (fr) * | 2022-01-26 | 2023-08-03 | Amarin Pharmaceuticals Ireland Limited | Compositions d'acides gras à libération de lymphe et leurs utilisations pour l'incorporation lymphatique et le traitement de maladies systémiques |
| CN116253891B (zh) * | 2022-08-22 | 2024-09-20 | 中南大学湘雅医院 | Chta-dsb-da高分子载体及其载药纳米材料的制备和在眼科药物中的应用 |
| KR102513994B1 (ko) * | 2022-10-26 | 2023-03-24 | 김태윤 | 반려동물의 눈물 착색예방용 조성물 |
| CN116196263A (zh) * | 2023-02-23 | 2023-06-02 | 河南大学 | 一种含有干细胞提取物的护肤组合物及其制备方法 |
| CN118477012B (zh) * | 2024-05-07 | 2025-01-21 | 广州品域美妆创新科技有限公司 | 一种含胶原的抗皱紧致组合物及其在化妆品中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL98747A0 (en) * | 1991-07-05 | 1992-07-15 | Yissum Res Dev Co | Ophthalmic compositions |
| US5744155A (en) * | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| DE69426062T2 (de) * | 1993-08-18 | 2001-03-22 | Alcon Laboratories, Inc. | Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms |
| US20100173876A1 (en) * | 2000-12-19 | 2010-07-08 | The Board Of Regents Of The University Of Texas System | Oil-based nsaid compositions and methods for making and using same |
| AR038628A1 (es) * | 2002-03-04 | 2005-01-19 | Novartis Ag | Composicion oftalmica |
| ES2256608T3 (es) | 2003-04-09 | 2006-07-16 | URSAPHARM ARZNEIMITTEL GMBH & CO. KG | Dispensador de fluidos. |
| JP5292277B2 (ja) * | 2006-03-31 | 2013-09-18 | ビスタコン・フアーマシユーチカルズ・エルエルシー | 眼アレルギーの処置 |
| WO2008035246A2 (fr) * | 2006-07-28 | 2008-03-27 | Novagali Pharma Sa | Compositions contenant des composés ammonium quaternaire |
| EP1985298A1 (fr) * | 2007-04-24 | 2008-10-29 | Azad Pharma AG | Émulsions ophtalmiques eau dans l'huile contenant des prostaglandines |
| US10201548B2 (en) * | 2009-03-06 | 2019-02-12 | Sun Pharma Global Fze | Methods for treating ocular inflammatory diseases |
| IN2012DN06581A (fr) * | 2010-03-17 | 2015-10-23 | Novaliq Gmbh | |
| DE102010023949A1 (de) * | 2010-06-16 | 2011-12-22 | F. Holzer Gmbh | In-situ Lecithin-Mikroemulsionsgel-Formulierung |
| DE102010050570A1 (de) * | 2010-11-05 | 2012-05-10 | F. Holzer Gmbh | Zusammensetzung und Arzneimittel enthaltend ω-3-Fettsäuren sowie einen Inhibitor des NF-κB-Transkriptionsfaktors |
-
2012
- 2012-05-15 EP EP12168139.9A patent/EP2664329A1/fr not_active Withdrawn
-
2013
- 2013-05-14 RU RU2014145440A patent/RU2014145440A/ru not_active Application Discontinuation
- 2013-05-14 US US14/401,464 patent/US20150139973A1/en not_active Abandoned
- 2013-05-14 CN CN201380025808.9A patent/CN104394859A/zh active Pending
- 2013-05-14 KR KR1020147035058A patent/KR20150014966A/ko not_active Withdrawn
- 2013-05-14 CA CA2873265A patent/CA2873265A1/fr not_active Abandoned
- 2013-05-14 MX MX2014013884A patent/MX2014013884A/es unknown
- 2013-05-14 JP JP2015512029A patent/JP2015521182A/ja active Pending
- 2013-05-14 AU AU2013261873A patent/AU2013261873A1/en not_active Abandoned
- 2013-05-14 WO PCT/EP2013/059927 patent/WO2013171204A2/fr not_active Ceased
- 2013-05-14 HK HK15102968.7A patent/HK1202427A1/xx unknown
- 2013-05-14 EP EP13723473.8A patent/EP2849741A2/fr not_active Withdrawn
- 2013-05-14 IN IN9594DEN2014 patent/IN2014DN09594A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HK1202427A1 (zh) | 2015-10-02 |
| WO2013171204A3 (fr) | 2014-01-09 |
| US20150139973A1 (en) | 2015-05-21 |
| CA2873265A1 (fr) | 2013-11-21 |
| EP2849741A2 (fr) | 2015-03-25 |
| JP2015521182A (ja) | 2015-07-27 |
| WO2013171204A2 (fr) | 2013-11-21 |
| KR20150014966A (ko) | 2015-02-09 |
| CN104394859A (zh) | 2015-03-04 |
| EP2664329A1 (fr) | 2013-11-20 |
| AU2013261873A1 (en) | 2014-12-04 |
| MX2014013884A (es) | 2015-06-23 |
| RU2014145440A (ru) | 2016-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN09594A (fr) | ||
| MX2020005217A (es) | Composicion oftalmica y dispositivo de administracion de la misma. | |
| MY159463A (en) | Method and composition for treating ocular hypertension and glaucoma | |
| WO2017158366A3 (fr) | Dispositif d'administration ophtalmique et compositions médicamenteuses ophtalmiques | |
| MY171920A (en) | Prevention and treatment of ocular conditions | |
| MX2015002239A (es) | Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares. | |
| HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
| UA114705C2 (uk) | Андрогенна композиція для лікування офтальмологічного захворювання | |
| BR112014018910A8 (pt) | Produto farmacêutico , kit, uso de vemurafenibe, produtos, métodos, composições e usos inovadores | |
| PH12015502539B1 (en) | Cenicriviroc compositions and methods of making and using the same | |
| MX2019000586A (es) | Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd). | |
| MX370853B (es) | Formulaciones que contienen dapagliflozina amorfa. | |
| CL2012002326A1 (es) | Uso de una combinación de por lo menos un agente quimioterapéutico y una cantidad efectiva de un anticuerpo anti-vegf (factor de crecimiento endotelial vascular), porque sirve para preparar un medicamento útil en el tratamiento de cáncer ovárico; y su kit para tratar el cáncer ovárico sin tratamiento anterior en una paciente humana. | |
| EP4414376A3 (fr) | Nouveau depsipeptide et ses utilisations | |
| GT201300235A (es) | Uso de 2,3-dihidroimidazo (1,2-c) quinazolinas sustituidas | |
| EA201400002A1 (ru) | Способы лечения заболеваний сетчатки | |
| WO2012080497A3 (fr) | Procédés de traitement et de prévention de maladies oculaires | |
| HK1198811A1 (en) | A medicament for treating anterior eye disease comprising rebamipide and a tear-retaining agent | |
| EA201201239A1 (ru) | Композиция, содержащая в качестве активного ингредиента l-карнитин в комбинации с гидроксикинуренин-о-бета-dl-глюкозидом, для предотвращения и/или лечения патологий глаза, вызванных ультрафиолетовым излучением | |
| EA201301332A1 (ru) | ОФТАЛЬМОЛОГИЧЕСКИЙ ПРЕПАРАТ, СОДЕРЖАЩИЙ АНАЛОГ PGF2α | |
| WO2016030899A8 (fr) | Méthodes de traitement de la sclérose latérale amyotrophique | |
| IN2014CN02972A (fr) | ||
| PH12012501271A1 (en) | Topical ophthalmic peptide formulation | |
| BR112018072127A2 (pt) | inibidores de dipeptidil peptidase-4 para o tratamento ocular tópico de doenças neurodegenerativas da retina | |
| BR112015019524A2 (pt) | tratamento de combinação |